新股消息 新济医药递表港交所

Core Insights - Guangzhou Xinji Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Guotai Junan acting as the sole sponsor [1] - Founded in 2007, the company is an innovation-driven pharmaceutical technology enterprise based in Guangzhou, China, currently in the clinical stage [1] - The company has developed two core technology platforms: (i) soluble microneedle formulation technology platform and (ii) nasal inhalation formulation technology platform [1] - Xinji Pharmaceutical has two core products and three additional pipeline products, with the first core product being a microneedle patch of dexmedetomidine hydrochloride for preoperative sedation in pediatric and adult patients [1] - As of December 18, 2025, the microneedle patch has entered Phase IIa clinical trials for pediatric patients in China, with NMPA approval for Phase II clinical trials in adult patients expected to start in Q1 2026 [1] - The second core product, XJN010, is a nasal inhalation formulation developed for on-demand treatment of "off" episodes in Parkinson's disease patients, which has also entered Phase II clinical trials in China as of December 18, 2025 [1]